Moreover, merestinib (LY2801653), a multi-kinase inhibitor with activity against MNKs among other protein kinases, inhibits tumor growth and metastasis in NSCLC models [78,79,80], and is currently used in clinical trials (phase II)—not only in NSCLC, but also in AML, biliary tract and colorectal cancer (Table 2). Here, WEE1 is linked to non-small cell lung carcinoma.